Liquidia Corporation (LQDA) - Stock Analysis
Last updated: May 9, 2026
Research Idea
Research content for general circulation. Not individualized advice.Ā Methodology & Disclosures
Strong operating inflection and price momentum: Q1 2026 YUTREPIA net product sales were about $130M, with more than 4,500 unique prescriptions, a third straight profitable quarter, net income around $53M, adjusted EBITDA of $71M, and free cash flow near $50M. Shares are up about 41% over 21 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ā¢ High Margins ā¢ Debt Pressure ā¢ Cash Strength LQDA has strong gross margins, improving quarterly profitability and liquidity, but full-year losses, heavy leverage, and a rich valuation keep the risk profile elevated.
Price Behavior
Key Price Behavior Insights: ā¢ Higher low ā¢ Fresh breakout ā¢ Hold $40 Support Level: $40.13 Resistance Level: $42.30 Over the last month, LQDA has turned constructive with a higher low and steady rebound to a fresh $42.30 high, but it remains vulnerable if it loses the $40 support area after its prior sharp drop.
Sentiment & News
Key News Insights: ā¢ Insider Selling ā¢ Analyst Upgrades ā¢ Q1 Results Heavy April insider selling pressured LQDA, but early-May analyst upgrades, conference participation, and an upcoming Q1 earnings report have turned sentiment more constructive.
AI Summary
LQDA's latest quarter shifts the thesis from āpromising biotechā to a possible commercial inflection story because it generated operating profit and free cash flow, but the stock is only worth chasing if that profitability proves durable given the real drag from Yutrepia legal risk, leverage, and competitive pressure that could quickly unwind the re-rating.
Description
Liquidia Corporation is a U.S.-based biopharmaceutical company that develops, manufactures and commercializes therapies to address unmet clinical needs. Its portfolio includes an inhaled dry powder formulation of treprostinil for pulmonary arterial hypertension and it also markets generic treprostinil injection domestically. The company was founded in 2004 and is headquartered in Morrisville, North Carolina.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| May 13 | May 20 | LQDA | Liquidia Corporation | Strong operating inflection and price momentum: Q1 2026 YUTREPIA net product sales were about $130M, with more than 4,500 unique prescriptions, a third straight profitable quarter, net income around $53M, adjusted EBITDA of $71M, and free cash flow near $50M. Shares are up about 41% over 21 trading days. | Active | +0.0% |